Tactical Resources Corp is an exploration & development company focused on the rare earth elements (REE) that drive the green technologies of the future. Its projects include Lac Ducharme Project, Peak Project, and SAM Gold Project.
相关临床试验
18
3 进行中
药物批准
6
批准总数
监管机构
1
监管机构数
成立时间
N/A
进行中（未招募）
3
16.7%
已完成
1
5.6%
招募中
14
77.8%
- The FDA granted standard full approval to Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) for pediatric mucopolysaccharidosis type IIIA, also known as Sanfilippo syndrome Type A. - Fayuvi is a one-time intravenous AAV9 gene therapy delivering a functional SGSH gene to restore the missing sulfamidase enzyme and reduce heparan sulfate accumulation. - Approval was supported by the pivotal Transpher A trial, in which treated patients scored 23.5 points higher on Bayley-III cognitive measures than an external natural history cohort (p<0.0001). - Ultragenyx expects commercial product to ship to Qualified Treatment Centers within 30-60 days, supported by its UltraCare program, and received a Priority Review Voucher.
- The U.S. FDA granted accelerated approval to GENGLYCOS (pariglasgene brecaparvovec-opnr), the first gene therapy for glycogen storage disease type Ia (GSDIa), in patients aged eight years and older. - Approval was based on the Phase 3 GlucoGene study, which showed a significant reduction in cornstarch requirements in treated patients (p<0.001). - GENGLYCOS is an AAV8-based gene therapy that directly targets the G6PC gene defect underlying GSDIa, reducing reliance on burdensome around-the-clock cornstarch regimens. - Ultragenyx received a Priority Review Voucher and will conduct a post-marketing Disease Monitoring Program to confirm clinical benefit under the accelerated approval pathway.
- Ultragenyx (RARE) received its first gene therapy approval from the FDA, driving the stock up 6% in after-hours trading. - The approval also granted Ultragenyx a Priority Review Voucher, which one Stocktwits user estimated to be worth approximately $200 million. - Retail sentiment on Stocktwits improved from "bullish" to "extremely bullish," with some users speculating about a potential big-pharma buyout of Ultragenyx. - RARE stock has gained 14% year-to-date, reflecting investor optimism around the company's regulatory milestone.
- Analysis of FDA Complete Response Letters from 2020 to 2024 reveals that 74% cited manufacturing or quality issues, pointing to organizational deficiencies rather than scientific failure as the primary constraint in drug development. - Three advanced therapy programs received CRLs on a single day in July 2025 — all for CMC deficiencies — underscoring a structural mismatch between how companies make capital commitment decisions and what compressed timelines now demand. - With 57% of 2024 FDA novel drug approvals involving expedited designations and AI compressing discovery timelines, companies must restructure manufacturing scale-up decisions, embed commercial functions earlier, and develop integrated leadership capable of decision-making under uncertainty. - Mid-sized biopharma companies face the greatest exposure, while therapeutic areas beyond oncology — including cardiovascular, CNS, metabolic disease, and immunology — remain largely unprepared for the accelerating development paradigm.
- The developmental and epileptic encephalopathies (DEE) market reached USD 2.2 billion across the 7MM in 2025, with the United States accounting for approximately 59% of the total market share. - The diagnosed prevalent population of DEE in the 7MM is projected to rise from approximately 288,000 in 2025 to 326,000 by 2036, reflecting improved genetic testing and diagnostic awareness. - A robust pipeline featuring antisense oligonucleotides, gene therapies, and precision medicines—including zorevunersen, bexicaserin, and relutrigine—is expected to reshape the treatment landscape for genetically defined DEE subtypes. - Praxis Precision Medicines' relutrigine received FDA Priority Review acceptance in March 2026 with a PDUFA target action date of September 27, 2026, for SCN2A and SCN8A DEEs.
- Northwest Biotherapeutics has appointed Dr. Annalisa Jenkins, a distinguished biopharma leader with over 25 years of experience, as Strategic Adviser to advance its DCVax® dendritic cell-based cancer vaccine platform. - The company's lead program DCVax®-L for glioblastoma has completed a 331-patient Phase III trial and submitted a Marketing Authorization Application to the UK's MHRA for commercial approval. - The DCVax® platform is designed to address solid tumors, which represent approximately 90% of all cancers, with clinical trials encompassing 16 diverse tumor types. - Dr. Jenkins brings extensive expertise from executive roles at major pharmaceutical companies including Merck Serono and Bristol-Myers Squibb, plus experience as CEO of gene therapy company Dimension Therapeutics.
- A phase 2 clinical trial of burosumab in 12 patients with fibrous dysplasia successfully restored phosphate levels to the mid-to-upper normal range in all participants by week 48. - Two severely affected children experienced transformational mobility improvements, with one progressing from full-time wheelchair use to independent walking and another achieving walker-assisted ambulation after never walking independently. - The monoclonal antibody treatment targeting FGF23 was well-tolerated and showed substantial reductions in alkaline phosphatase levels, a marker of disease activity, by 49% at week 48. - Results support targeting higher phosphate levels than previously used in other FGF23 excess disorders, potentially offering a new therapeutic approach for this rare skeletal condition.
- Over 180 companies are advancing 250+ AAV-based gene therapy candidates globally, spanning preclinical through marketed stages, according to DelveInsight's 2026 pipeline assessment. - The FDA granted approval to Otarmeni, the first dual-AAV gene therapy for OTOF-related genetic hearing loss, and accepted Ultragenyx's BLA for UX111 in Sanfilippo syndrome Type A with a September 2026 PDUFA date. - Taysha Gene Therapies reported FDA alignment on a BLA pathway for TSHA-102 in Rett syndrome, with pivotal REVEAL trial enrollment progressing and manufacturing validation underway. - Sensorion's SENS-501 demonstrated durable efficacy and favorable safety at six months in a Phase I/II trial for otoferlin-related congenital hearing loss, while GJB2-GT advances toward regulatory filing.
- The U.S. Food and Drug Administration has cleared Ultragenyx Pharmaceutical's Investigational New Drug application for UX016, a sialic acid prodrug designed to treat GNE myopathy. - GNE myopathy is a rare, severely debilitating neuromuscular disease affecting approximately 10,000 people globally, with no currently approved therapy in the United States. - UX016 is an investigational small-molecule prodrug that combines sialic acid with a C16 fatty acid tail to improve biodistribution to muscle tissues. - The FDA clearance enables Ultragenyx to initiate clinical trials evaluating UX016's safety and efficacy in addressing this progressive muscle-wasting disorder.
- Amlogenyx announced positive preclinical results for AM805, an AAV9 gene therapy that delivers protective protein cathepsin A (PPCA) to reduce amyloid burden in Alzheimer's disease models. - The therapy demonstrated dose-dependent amyloid reduction in both severe and moderate mouse models, with effects comparable to or exceeding approved monoclonal antibodies. - AM805 successfully cleared both intracellular and extracellular amyloid across multiple administration routes, showing therapeutic effectiveness regardless of delivery method. - The company plans to submit an Investigational New Drug (IND) application to the FDA in 2027 following completion of IND-enabling studies.
